Insulin Resistance Syndrome Metabolic Syndrome Syndrome X
Conditions
Interventions
At the start of the study, the participants will have a baseline test day. On
this test day, the subjects will only receive a high fat milkshake and the 3
hours after ingestion of the milkshake will
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Men - Aged between 40-70 years - Waist circumference >= 102 - Fasting plasma glucose
Exclusion criteria
Exclusion criteria: - Women - Fasting plasma glucose >= 7.0 mmol/L - Fasting serum total cholesterol >= 8.0 mmol/L - Current smoker, or smoking cessation 3 kg in the past three months) - Use medication known to treat blood pressure, lipid or glucose metabolism - Use of an investigational product within another biomedical intervention trial within the previous 1-month - Intolerance or allergy to the intervention products (e.g. lactose or gluten) - Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis - Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident - Not willing to give up being a blood donor from 8 weeks before the start of the study, during the study or for 4 weeks after completion of the study - Not or difficult to venipuncture as evidenced during the screening visit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurements will be performed before and two hours after consumption of the high fat milkshake and the five interventional products. The primary endpoint is the difference in postprandial change in FMD between the five interventional products. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are the postprandial effects of the interventional products on retinal microvascular function, plasma cGMP (as indicator of nitric oxide bioactivity), plasma markers for low-grade systemic inflammation and endothelial dysfunction, blood pressure, and serum lipid and plasma glucose metabolism. | — |
Countries
Netherlands
Outcome results
None listed